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Pathology consistent with that observed in Alzheimer’s disease (AD) has previously
been documented following intranasal infection of normal wild-type mice with Chlamydia
pneumoniae (Cpn) isolated from an AD brain (96-41). In the current study, BALB/c mice
were intranasally infected with a laboratory strain of Cpn, AR-39, and brain and olfactory
bulbs were obtained at 1–4 months post-infection (pi). Immunohistochemistry for amyloid
beta or Cpn antigens was performed on sections from brains of infected or mock-infected
mice. Chlamydia-speciﬁc immunolabeling was identiﬁed in olfactory bulb tissues and in
cerebrum ofAR-39 infectedmice.The Cpn speciﬁc labelingwasmost prominent at 1month
pi and the greatest burden of amyloid deposition was noted at 2 months pi, whereas both
decreased at 3 and 4 months. Viable Cpn was recovered from olfactory bulbs of 3 of 3
experimentally infected mice at 1 and 3 months pi, and in 2 of 3 mice at 4 months pi. In
contrast, in cortical tissues of infected mice at 1 and 4 months pi no viable organism was
obtained. At 3 months pi, only 1 of 3 mice had a measurable burden of viable Cpn from the
cortical tissues. Mock-infected mice (0 of 3) had no detectable Cpn in either olfactory bulbs
or cortical tissues. These data indicate that the AR-39 isolate of Cpn establishes a limited
infection predominantly in the olfactory bulbs of BALB/c mice. Although infection with
the laboratory strain of Cpn promotes deposition of amyloid beta, this appears to resolve
following reduction of the Cpn antigen burden over time. Our data suggest that infection
with the AR-39 laboratory isolate of Cpn results in a different course of amyloid beta
deposition and ultimate resolution than that observed following infection with the human
AD-brain Cpn isolate, 96-41. These data further support that there may be differences,
possibly in virulence factors, between Cpn isolates in the generation of sustainable AD
pathology.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common dementia in the
US, accounting for 50–70% of cases. More than 5 million Ameri-
cans are living with a diagnosis of AD as of 2013 with 90–95% of
cases in the 65 and older segment of the population. Early stage of
disease involves memory impairment (Fargo and Bleiler, 2014). In
the advanced stages of AD, individuals require assistancewith daily
activities and, ultimately, in the ﬁnal stage become bed-bound and
are reliant on around-the-clock care (Hebert et al., 2003). AD is
a fatal disorder with the progression from the earliest symptoms
to total functional dependency and death in an untreated per-
son often occurring within 8–10 years post-diagnosis (Fargo and
Bleiler, 2014).
Although much is known about the disease process and pro-
gression of AD, the initiating factors or cause(s) of the disease still
remain a mystery. AD has an early onset or “familial form” that
is an autosomal dominant disorder, primarily driven by genetic
alterations in genes encoding the beta amyloid precursor protein
or the loci encoding the enzymes that process this precursor, prese-
nilins 1 and 2 (Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev
et al., 1995; Wolfe, 2007). Transgenic mouse models have been
developed with enhanced β-amyloid production and deposition
(Wisniewski and Sigurdsson, 2010; Hall and Roberson, 2012), and
serve as models for the “early onset” familial form of AD, which
accounts for 5% or fewer of all reported cases. One deﬁciency of
these model systems is how to target the early initiating events
in sporadic late-onset AD and not just the “tombstone” lesions
that are the result of years or decades of progressive pathologi-
cal processes (Wisniewski and Sigurdsson, 2010). In this regard,
animal models that mimic aspects of the sporadic late-onset form
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of AD have been developed, but lack a clear understanding of
the primary factors promoting β-amyloid deposition. Models that
have been used to experimentally induce AD-like pathology in
the central nervous system (CNS) have focused on chronic stress
(Alkadhi et al., 2010), chemical induction with colchicine (Kumar
et al., 2007), and bacterial toxins such as streptozotocin (Labak
et al., 2010; for review see Balin et al., 2011). A limited num-
ber of infectious agents, including Chlamydia pneumoniae (Cpn),
have been proposed to enhance risk or play a contributing or
causal role in AD (Balin et al., 1998; Gerard et al., 2006); animal
models have been developed to study the effects of this infection
(Little et al., 2004, 2005) with regards to AD-like pathology. How-
ever, there remains a dearth of experimental animal systems that
accurately model the initiation and progression of sporadic/late-
onset AD, leaving researchers with limited options to address
pertinent questions pertaining to these important aspects of this
chronic disease.
The identiﬁcation of Cpn in AD brain tissue (Balin et al.,
1998) was the impetus to investigate the potential role of infec-
tion, with this obligate intracellular bacterium, in the induction
and progression of late-onset AD and led to the establishment
of a mouse model to investigate this occurrence (Little et al.,
2004). In the original experimental system, BALB/c mice were
infected with Cpn recovered from AD brain tissue. The isolate
of Cpn, 96-41, was brieﬂy propagated in an epithelial cell line
and then used to infect 3 months old BALB/c mice intranasally;
brain tissue was analyzed for AD-like pathology at monthly
intervals up through 3 months pi following infection in this
manner.
This initial study utilized the human AD-brain isolate of Cpn
to evaluate whether AD-like pathology was an outcome in non-
transgenic mice (Little et al., 2004), and was designed to address
Koch’s postulates. To fulﬁll the ﬁrst postulate, the infectious organ-
ism must be isolated from tissues of an affected individual. In
this particular case, the ﬁrst postulate was satisﬁed, but for other
cases this issue is still debated (Itzhaki et al., 2004). Koch’s second
postulate dictates that the pathogen be isolated from a diseased
organism followed by growth in pure culture. The bacterium
was isolated post-mortem from AD-brain tissue and grown in
culture within a host cell as this is an obligate intracellular bac-
terium. Third, the organism was introduced into a mouse via
the natural route of infection, and induced pathology consis-
tent with AD, while mice receiving vehicle alone did not display
the same pathology. Koch’s fourth postulate stipulates that the
organism be re-isolated from affected animals; in this instance,
Cpn was identiﬁed in the tissues of affected mice, but was not
re-isolated from the tissue (Balin et al., 2011). Koch’s postulates
were used as a general guide, and when studying an intracellular
infection these observations are consistent with the hypothesis
that Cpn infection can induce AD-like pathology, speciﬁcally
β-amyloid deposition, in the brain and contribute directly to
pathogenesis.
In mice infected with Cpn, a detectable difference in β-amyloid
deposits was observed at 2 months pi, and a greater number of
deposits were identiﬁed at 3 months pi. The increase in both the
number and size of amyloid deposits at later timepoints indicated
that there was progressive development of AD-like pathology.
The experimental induction of BALB/c mouse derived β-amyloid
deposits at 5 and 6 months of age (2 and 3 months pi) also
suggests that infection was directly responsible for the produc-
tion and deposition of this β-amyloid. In contrast, in transgenic
mouse models used to study AD, substantial amyloid deposits
are not typically found at 3 or even 6 months of age, yet sub-
stantial pathology was induced within 3 months following the
introduction of the infectious agent into this non-transgenic
mouse model of sporadic AD (Little et al., 2004). As Cpn is
typically associated with an acute respiratory illness, introduc-
tion into BALB/c mice was via intranasal inoculation, the natural
route of infection. Additional experimental evidence supports the
hypothesis that the respiratory infection precedes dissemination
to other organ systems (Little et al., 2005). In this regard, while
spread of the organism occurs in younger animals, it is even
more apparent with the advent of immunosenescence in older
animals.
In contrast with the initial report associating Cpn with the
induction of AD-like pathology in the brains of BALB/c mice
(Little et al., 2004), the current study was performed with a respi-
ratory isolate and common laboratory strain of Cpn, AR-39. The
purpose was to determine if this well-studied laboratory isolate
of Cpn would induce pathology in a similar manner and to the
same degree over a similar time course, as that observed for the
human CNS isolate used previously. This approach will inform
potential differences in outcomes when infecting mice with Cpn
originally isolated from lung tissues andused as a laboratory isolate
as compared to that from human AD brain.
MATERIALS AND METHODS
HEp-2 CELL LINE
The human epithelial, HEp-2, cell line (ATCC, Rockville, MD,
USA) was cultured in minimal essential medium (MEM) sup-
plemented with 10% fetal bovine serum (FBS; Cellgro Mediatech,
Inc.,Manassas,VA,USA), 5mML-Glutamine (Thermo Fisher Sci-
entiﬁc, Pittsburgh, PA,USA) at 37◦C and 5%CO2. 1–2 × 105 cells
were plated in a T25 tissue culture ﬂask (Thermo Fisher Scientiﬁc,
Pittsburgh, PA, USA) and passaged as needed prior to collection
for the propagation of Cpn.
PROPAGATION AND PURIFICATION OF Chlamydia pneumoniae
Chlamydia pneumoniae, AR-39 isolate, was obtained from the
ATCC (ATCC, Rockville, MD, USA) and propagated in the
HEp-2 cell line similar to that described for the Cpn brain iso-
late, 96-41 (Campbell et al., 1991; Little et al., 2004). Prior to
infection of BALB/c mice, homogenates of 72 h culture super-
natants and Cpn infected HEp-2 cells were sonicated for 30 s
and passed through a series of ﬁlter membranes with decreas-
ing pore size to collect the elementary bodies. The organism was
resuspended in Hanks balanced salt solution (HBSS), aliquoted,
and stored at –80◦C. The quantiﬁcation of inclusion forming
units (IFUs) subsequently was determined following infection
of HEp-2 epithelial cells with a series of 10-fold serial dilu-
tions of the concentrated organism. The inclusions were iden-
tiﬁed by immunoﬂuorescence using a Chlamydia-speciﬁc anti-
body (ImagenTM; DAKO, Carpenteria, CA, USA). Immediately
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preceding infection, aliquots were diluted in HBSS for the
intranasal infection of mice.
MICE
Six week old female BALB/cJ mice were purchased from Jackson
Laboratories (Bar Harbor, ME, USA) and acclimated for 2 weeks
prior to the initiation of experiments. Mice were housed in groups
of 2–3 in HEPA-ﬁlter caged racks, with infected mice housed sep-
arately from uninfected mice, within the bio-containment facility
at the Philadelphia College of Osteopathic Medicine. All animal
husbandry was performed using Biosafety Level 2 precautions and
in a Class II biosafety cabinet. Mice were fed food and water ad
libitum. All animal protocols were approved by the IACUC at
PCOM.
INFECTION OF MICE WITH Chlamydia pneumoniae
Under manual restraint, 8 week old, female BALB/cJ mice were
inoculated intranasally with 5 × 105 IFUs of the AR-39 isolate of
Cpn diluted in 50 μl of HBSS. Six mice were inoculated at 8 weeks
of age for each time point and the brains were collected at 1, 2,
3, and 4 months post-infection (pi) for analysis. Four age and
sex matched mice were mock-intranasally infected with vehicle
alone, HBSS, as a control for each time point. At each time point,
three experimentally infected and twomock-infected controlmice
were anesthetized, cardiac-perfused and organs were collected
and immersion ﬁxed in 4% paraformaldehyde for embedding,
sectioning, and immunohistochemical analysis. The remaining
three experimentally infected and twomock-infected controlmice
at each time point other than for 2 month animals for which
frozen tissue was not available were euthanized and organs were
collected and snap-frozen in liquid nitrogen and then stored
at –80◦C until analysis for detection and quantiﬁcation of viable
organism.
RECOVERY AND QUANTIFICATION OF Chlamydia pneumoniae
Quantiﬁcation of viable Cpn was performed in an identical man-
ner to our previous report (Little et al., 2005) in the following
manner. Frozen tissue was thawed and a 10% weight to vol-
ume homogenate was prepared in serum-free MEM (Thermo
Fisher Scientiﬁc, Pittsburgh, PA, USA) supplemented with 2 mM
Glutamine. Serial 10-fold dilutions (in 200 μL) were added
to four well Lab Tech chamber slides (Naperville, IL, USA)
on which HEp-2 cells were previously plated. Negative con-
trol wells contained cells mock-infected with medium alone.
Chamber slides were incubated at 37◦C in 5% CO2 for 2.5 h,
washed with HBSS and reﬁlled with fresh complete medium
supplemented with 2 μg/ml cycloheximide (Sigma-Aldrich, St.
Louis, MO, USA) followed by incubation for 48 h at 37◦C.
After incubation, slides were washed with HBSS, ﬁxed in 50%
methanol at RT for 20 min, washed twice in HBSS, and labeled
with a 1:10 dilution of FITC-conjugated Chlamydia-speciﬁc anti-
body (ImagenTM; DAKO, Carpenteria, CA, USA) for 90 min
at 37◦C, protected from light. Slides were washed in phosphate
buffered saline (PBS) and counterstained with a 2 μg/ml of Bis-
benzamide (Sigma-Aldrich, St. Louis, MO, USA) in PBS for
1 min, washed in PBS and coverslipped with aqueous mount-
ing medium (ImagenTM; DAKO, Carpenteria, CA, USA). All
titers are calculated as IFUs/ml of 10% weight to volume tissue
homogenate.
ANTIBODIES
The following Chlamydia-speciﬁc antibodies were generated in
mice: RDI-PROAC1p (Research Diagnostics Incorporated, Flan-
ders, NJ, USA; AC1P; monoclonal IgG) speciﬁc for Chlamydia
lipopolysaccharide used at a dilution of 1:10 (5 μg/ml), M6600
(DakoCytomation, Carpinteria, CA, USA; monoclonal IgG) spe-
ciﬁc for Cpn major outer membrane protein used at a dilution of
1:10 (10 μg/ml), and 10C-27 (Fitzgerald, Concord, MA, USA;
monoclonal IgG) speciﬁc for Cpn used at a dilution of 1:100
(1 μg/ml). Additionally, B65256R (Biodesign International, Saco,
ME, USA; B56R) speciﬁc for Chlamydia puriﬁed elementary bod-
ies was generated in rabbit and used at a dilution of 1:200
(2 μg/ml). Both secondary antibodies speciﬁc for either mouse,
AP-Goat anti-mouse IgG conjugate (Zymed Laboratories, San
Francisco, CA, USA), or rabbit, AP-Goat anti-rabbit IgG conju-
gate (Zymed Laboratories, San Francisco, CA, USA), were used at
a concentration of 2μg/ml. All antibodies were diluted to working
concentration in 2%FBS/PBS blocking buffer (ThermoFisher Sci-
entiﬁc, Pittsburgh, PA,USA). For the detection of Aβ-amyloid, the
following antibodies were used at a recommended concentration
of 2 μg/ml: a rabbit polyclonal antibody speciﬁc for the carboxyl-
terminal fragment of Aβ amyloid 1–42 (catalog: A1976 Oncogene
Research Products, Boston, MA, USA), and a mouse monoclonal
antibody (4G8) to the 17–24 amino acid peptide of human Aβ
amyloid 1–42 (catalog:9220-05 Signet Laboratories Inc., Dedham,
MA, USA). For all amyloid-speciﬁc immunolabeling, secondary
antibodies consisted of HRP conjugated sheep anti-Mouse IgG (H
+ L) or donkey anti-rabbit IgG (H + L). Antibodies were used at a
dilutionof 1:300 as recommendedby the supplier (AmershamBio-
sciences, Piscataway, NJ, USA and Life Technologies, Inc., Grand
Island, NY, USA).
IMMUNOHISTOCHEMISTRY
Brain sections from experimental and controlmice were immuno-
labeled for Aβ-amyloid or Cpn antigen at 1, 2, 3, and 4 months
pi using the aforementioned antibodies. Coronal sections were
deparafﬁnized with xylene (Thermo Fisher Scientiﬁc, Pittsburgh,
PA, USA) rehydrated in a series of graded alcohol solutions (Elec-
tron Microscopy Sciences, Fort Washington, PA, USA), followed
by de-ionized (DI) H2O. Slides were then placed in Citra antigen
retrieval buffer (BioGenex, San Ramon, CA, USA) and steamed
in a 2100 Retriever (Pick Cell Laboratories, Amsterdam, Nether-
lands) for 20 min at high pressure and temperature (120◦C).
Slides were then rinsed with PBS pH 7.4 (Sigma-Aldrich, St
Louis, MO, USA) 3 × 5 min. Endogenous peroxidase activity
was quenched utilizing a 3% solution of H2O2/PBS (Thermo
Fisher Scientiﬁc, Pittsburgh, PA, USA) for 5 min at RT. Sections
were rinsed 1 × 5 min in PBS and blocked 3 × 15 min in 2%
heat inactivated FBS/PBS. A total of 30 coronal brain sections,
10 sets of three sections (one per antibody), were immunola-
beled permouse. The sections were spaced equally (approximately
every 70–100 microns in brain tissue) from rostral (bregma
+2.22 mm) to caudal (bregma –5.88 mm) in order to pro-
vide samples representative of the regions spanning the entire
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brain of each mouse. Slides receiving Chlamydia-speciﬁc pri-
mary antibodies B56R or a cocktail of 10C-27, AC1P,M6600 were
applied to tissue sections and placed in a humidiﬁed chamber
at 37◦C for 90 min. The sections were rinsed 3 × 5 min each
and then blocked 3 × 15 min each in 2% FBS/PBS, and incu-
bated with appropriate secondary antibodies for 1 h at 37◦C.
Next, sections were rinsed with DI H2O 3 × 5 min and devel-
oped using alkaline phosphatase new magenta for 15 min (BioFX,
Owings Mills, MD, USA) at RT. Sections were rinsed in DI
H2O 3 × 5 min followed by one PBS rinse for 5 min. Acidi-
ﬁed Harris’s Hematoxylin (Thermo Fisher Scientiﬁc, Pittsburgh,
PA, USA) was applied to sections for 1 min. One DI H2O rinse
followed counterstaining and the sections were contrasted in
PBS for 5 min. Finally, the sections were rinsed with DI H2O
3 × 5 min, air dried, and crystal mounted (BioMeda, Foster
City, CA, USA). Once dry, the sections were permounted and
coverslipped.
Slides receiving mouse primary antibodies were blocked in
mouse on mouse (M.O.M.) IgG blocking reagent (Vector M.O.M.
kit, Vector Laboratories, Burlingame, CA, USA) for 60 min at
RT, rinsed, and incubated for 5 min in the M.O.M. blocking
buffer. Following blocking, primary antibodies were added to
samples and incubated overnight at 4◦C. The sections were rinsed
in PBS 3x for 5 min each, blocked 3x for 15 min each in 2%
FBS/PBS, and incubated with appropriate secondary antibodies
for 120min at RT. The sections labeledwith anti-amyloid antibod-
ies were rinsed with PBS 3x for 10 min each and visualized with
3, 3’-Diaminobenzidine (DAB; Sigma FASTTM, Sigma-Aldrich,
St. Louis, MO, USA). Sections were rinsed with dH2O, counter-
stained with Harris’ Alum Hematoxylin for 1 min (EM Sciences
Harleco®, EM Industries, Inc., Hawthorne, NY, USA), dehydrated
and permounted.
MICROSCOPIC ANALYSIS
Digital images were captured using Image-Pro Plus Phase 3 Imag-
ing System software (Media Cybernetics, Silver Spring, MD, USA)
on a Nikon Eclipse E800 microscope using a Spot RT Camera
(Diagnostic Instruments, Sterling Heights, MI, USA).
STATISTICAL ANALYSIS
Statistical analysis was performed using the student t-test fol-
lowed by pair-wise testing of uninfected (n = 8) relative to each
experimental infected timepoint (n = 3) using Microsoft excel
statistical analysis software and P values of <0.05 which were
considered signiﬁcant.
RESULTS
RECOVERY OF INFECTIOUS Chlamydia pneumoniae FROM OLFACTORY
BULBS AND CEREBRUM
Olfactory bulbs and cerebral tissues were dissected from BALB/c
mice following euthanization, snap-frozen, and homogenized
prior to incubation with HEp-2 cells in culture to determine
if detectable levels of viable Cpn could be recovered from the
CNS. Ten-fold serial dilutions of the homogenized tissues were
incubated with HEp-2 cells to determine the amount of viable
infectious Cpn present in the tissues at 1, 3, and 4 months pi.
Tissue from the 2 month animal was not available. Infectious
Cpn was recovered and quantiﬁed from 3 of 3 olfactory bulbs
at 1 month pi, ranging from 3 × 103 to 3 × 105 IFU/ml of tissue
homogenate (Figure 1A). At 3 months pi, Cpn was detected in 3
of 3 olfactory bulbs with a range of 2 × 105 to 3 × 106 IFU/ml of
tissue homogenate (Figure 1A). At 4 months, Cpn was detected
in 2 of 3 olfactory bulbs with a range of 0 to 2 × 106 IFU/ml
tissue homogenate (Figure 1A). Of the three olfactory bulbs
tested from the mock-infected animals, no Cpn was recovered.
In contrast to the olfactory bulbs, Cpn was not recovered from
the brain tissue (cerebrum) at 1 and 4 months pi, although at
3 months, Cpn was recovered and quantiﬁed at 3 × 104 IFU/ml
of tissue from 1 of 3 brains (Figure 1B). This same mouse had
3 × 105 IFU/ml in the olfactory bulb as noted above.With regards
to brain tissues analyzed from the three control animals, no Cpn
was detected.
FIGURE 1 | Recovery of viable Chlamydia pneumoniae from olfactory
bulb and brain tissues following intranasal infection. (A) At 1, 3, and
4 months post-infection (pi), viable Cpn was recovered from olfactory bulb
tissue homogenates of eight BALB/c mice, 3 of 3 mice at 1 month pi, 3 of 3
mice at 3 months pi, and 2 of 3 mice at 4 months pi. (B) In contrast, only 1
mouse demonstrated viable Cpn from cerebral cortical tissue at any time; that
being one mouse at 3 months pi. Viable Cpn was quantiﬁed as infectious
forming units/ml of tissue homogenate.
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IDENTIFICATION AND DISTRIBUTION OF Chlamydia pneumoniae
ANTIGEN IN THE CENTRAL NERVOUS SYSTEM
Cpn antigen was detected in olfactory bulb tissues at 1 and
3months pi using antibodies speciﬁc for Cpn LPS and outermem-
brane proteins. Representative immunolabeling for Cpn in these
tissues at 1 month pi was principally intracellular (Figure 2). The
labeling proﬁles consisted of large intracellular vacuoles, often
perinuclear with prominent well-deﬁned inclusions. Further-
more, Cpn antigen labeling (LPS and outer membrane proteins)
was documented within the cerebrum with a quantitative anal-
ysis of 10 total slides per animal distributed rostral to caudal
with distances measured from bregma (Table 1). Intracellu-
lar immunolabeling was observed to be both perinuclear and
diffuse in the cytoplasm with very few clearly documentable
intracellular inclusions (Figure 3). However, upon close exami-
nation, punctate immunolabeling was observed in numerous cells
(Figures 3C,E).
Quantitative analysis of Cpn antigen in the brain at 1 through
4 months post-intranasal inoculation revealed peak Cpn antigen
burden (154 immunoreactive proﬁles) at 1 month (Table 1A).
Cpn-speciﬁc immunoreactivity demonstrated a step-wise decrease
at 2, 3, and 4 months pi with 134, 91, and 76 immunoreac-
tive proﬁles, respectively. With regards to speciﬁc coordinates
in the brain, the greatest Cpn antigen burden (i.e., 42 Cpn
FIGURE 2 | Chlamydia pneumoniae specific immunoreactivity in
olfactory bulbs. Cpn (AR-39) antigens were detected in olfactory bulb
tissues at 1 month pi following intranasal inoculation (arrows). (A,B) are
from 1 infected mouse and (C,D) from a separate mouse infected with Cpn
and labeled with a cocktail of anti-Cpn antibodies (RDI-PROAC1p, M6600,
10C-27). (E,F) are representative images from mock-infected mice
comparably immunolabeled. Mag bars (A–F) = 50 μm.
immunoreactive proﬁles) was documented at 1 month in mul-
tiple sections 3.8 mm caudal to bregma. These sections contain
the entorhinal cortex (Ect), perirhinal cortex (Prh), hippocampus,
and amygdala, all regions affected in AD. A low but detectable
number of non-speciﬁc Cpn immunoreactive sites were detected
within mock-infected control mouse brain tissue with an aver-
age number of 0.355/section analyzed. The mean number of
immunoreactive sites identiﬁedwas 7.125/mouse±4.01 andbased
upon the results of the student t-test a statistically signiﬁcant dif-
ference (p < 0.05) was observed between experimentally infected
tissue and mock-infected control mouse tissue at all timepoints
analyzed; 1 month pi (51.33 ± 32.01), 2 months pi (44.67 ±
33.56), and 3 months pi (30.33 ± 12.06). No statistically sig-
niﬁcant difference was observed in the 4 month pi (25.33 ±
24.21) experimental group relative to uninfected control tissue
(Table 1B).
IDENTIFICATION AND DISTRIBUTION OF AMYLOID ANTIGEN IN THE
CENTRAL NERVOUS SYSTEM
Antibodies speciﬁc for amyloid beta 1–40 (Aβ 1–40) and amyloid
beta 1–42 (Aβ 1–42) were used to determine if immunoreactive
deposits could be detected in mock-infected controls and exper-
imentally infected BALB/c mice. A limited number of Aβ 1–40
immunoreactive deposits were observed exclusively in the brains
of experimentally infected mice at 2 months pi (data not shown).
No Aβ 1–40 deposits were detected in the brains of any control
mice at any timepoint nor in experimentally infected mice at 1, 3,
and 4 months pi.
Quantitative analysis of amyloid burden revealed the highest
number of Aβ 1–42 immunoreactive deposits (43) at 2 months
pi 3.8 mm caudal to bregma, similar to Cpn immunoreactivity
at 1 month pi (Table 1A). Overall Aβ 1–42 immunoreactivity
was greatest at 2 months pi, having been minimal at 1 month
pi and decreasing at 3 and 4 months pi. As noted above, these
sections contain the Ect, Prh, cerebral peduncle (Cp), hippocam-
pus, and amygdala, all regions affected in AD (see Figure 4 for
Aβ 1–42 immunoreactive deposits). A low but detectable num-
ber of amyloid-speciﬁc immunoreactive sites were detected within
mock-infected control mouse brain tissue at 2, 3, and 4 months
pi with an average number of 0.17/section analyzed. The mean
number of immunoreactive sites identiﬁed was 3.38/mouse ±
2.28 and based upon the results of the student t-test a statis-
tically signiﬁcant difference (p < 0.05) was observed between
experimentally infected tissue and mock-infected control mouse
tissue at 2 months pi (60/mouse ± 8) and 3 months pi (17.67
± 0.67). No statistically signiﬁcant difference was detected at
1 month pi (3.33 ± 1.17) or 4 months pi (21.83 ± 19.08;
Table 1B).
DISCUSSION
This study was designed as a follow-up investigation to the ini-
tial report of experimental induction of AD-like pathology in
BALB/c mice following intranasal inoculation with C. pneumo-
niae (Little et al., 2004). The key difference in the current study
as compared to that by Little et al. (2004) was that the AR39 res-
piratory lab strain was used to evaluate the effects in the brain
as compared to the 96-41 brain strain used in the initial report.
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Table 1 | Location of Chlamydia pneumoniae immunoreactivity and Aβ 1–42 amyloid deposits over 4 months pi within brains of Cpn-infected
mice.
A
Bregma Total
2.22 1.7 0.38 –1.28 –2.75 –3.8 –4.92 –5.46 –5.88 Inf Un
1 Mo Cpn 22 10 22 18 23 42 9 6 2 154 24
Amyloid 0 1 0 3 3 0 2 1 0 10 0
2 Mo Cpn 18 15 19 5 26 21 20 10 0 134 14
Amyloid 8 30 11 16 31 43 35 6 0 180 12
3 Mo Cpn 11 11 13 22 5 9 9 4 7 91 10
Amyloid 0 9 14 7 4 3 3 11 2 53 10
4 Mo Cpn 0 11 13 15 13 10 10 1 3 76 9
Amyloid 0 0 3 6 3 1 5 1 0 19 5
Cpn 51 47 67 60 67 82 48 21 12 455 57
Amyloid 8 33 12 5 32 19 33 1 0 143 27
B
Chlamydia-specific immunoreactivity Amyloid deposits
Uninfected (n = 2) Infected (n = 3) Uninfected (n = 2) Infected (n = 3)
Time pi mean SD Mean SD Time pi Mean SD Mean SD
1 12 5.65 51.33* 32.01 1 0 0 3.33 1.167
2 7 2.83 44.67* 33.56 2 6 1 60* 8
3 5 1.41 30.33* 12.06 3 5 1 17.67* 0.67
4 4.50 0.71 25.33 24.21 4 2.5 1.5 6.33 2.167
ALL 7.13 4.02 37.92 21.22 ALL 3.38 2.28 21.83 19.08
(A)The location and number of immunoreactive amyloid deposits or Cpn antigen is designated in millimeters (section location in mm) rostral or caudal to the
mouse bregma. (B) Statistical analysis of Cpn-speciﬁc immunoreactivity and Aβ 1–42 immunoreactive deposits from infected and uninfected mouse brains. For
each time point, n = animals analyzed, *indicate statistical signiﬁcance.
Chlamydia-speciﬁc immunolabeling was identiﬁed in olfactory
bulb tissues and in brains (cortical tissues) of AR-39-infected
mice. The Cpn-speciﬁc labeling was most prominent at 1 month
pi and the greatest burden of amyloid deposition was noted at
2 months pi, whereas both decreased at 3 and 4 months pi. The
majority of amyloid deposits at these times were immunoreac-
tive for Aβ 1–42. Interestingly, a limited number of Aβ 1–40
immunoreactive deposits also was identiﬁed (data not shown),
but only at the 2 month time point, the time of peak amyloid
burden. Viable Cpn was recovered from the olfactory bulb tis-
sues of 3 of 3 experimentally infected mice at 1 and 3 months
pi, and 2 of 3 at 4 months pi. In contrast, in cerebral corti-
cal tissues of experimentally infected mice, only at 3 months pi
did 1 of 3 mice have a measurable burden of viable Cpn. Mock-
infected control mice had no detectable Cpn in either olfactory
bulbs (0 of 3) or cortical tissues (0 of 3). These data indicate that,
following intranasal infection, the AR-39 respiratory isolate of
Cpn establishes a limited infection predominantly in the olfactory
bulbs of BALB/c mice. Furthermore, although infection with the
laboratory strain of Cpn promotes deposition of Aβ-amyloid, this
appears to resolve following reduction of the Cpn antigen burden
over time.
In our current study, brains were analyzed at 1 through
4 months pi by immunohistochemistry using speciﬁc antibod-
ies for both Chlamydia antigen and Aβ-amyloid 1–42. Similar to
our initial report utilizing the AD-brain isolate 96-41, no substan-
tial amyloid deposits were observed at 1 month pi with AR-39
and only a limited degree of pathology was identiﬁed at 2 months
pi. In contrast to the original study using the brain isolate, at
4 months pi, AD-like pathology was comparable to that observed
in mock-infected mice as well as infected mice at 1 month pi, sug-
gesting a decrease of pathology between 2 through 4 months pi.
Identiﬁcation and quantitative analysis of the Chlamydia burden
indicated that peak antigen burden preceded the peak deposition
of amyloid. The greatest Chlamydia antigen burden in infected
BALB/c mice was noted at 1 month pi, and decreased at 2 through
4 months pi, whereas peak amyloid burden was at 2 months pi,
and decreased thereafter. Taken together, the relationship between
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FIGURE 3 | Chlamydia pneumoniae specific immunoreactivity in the
central nervous system. Representative images of Cpn-speciﬁc antigen
labeling in the brains of infected mice at 1 month (A,B), 3 months (C,D),
and 4 months (E,F) pi. The upper right corner of each image is a higher
magniﬁcation image of Cpn-speciﬁc antigen labeling as designated by the
low magniﬁcation arrow. Mag bars = 50 μm.
Chlamydia antigen burden and the number of amyloid deposits
suggests that Cpn infection is a primary trigger for Aβ-amyloid
processing and deposition in brain tissues (Balin et al., 2011).
While consistent co-localization of amyloid with Chlamydia anti-
gen was not apparent, both were present in the same regions at
times consistent with AD-like pathology. As the course of infec-
tion preceded the course of pathology development, infectionmay
serve as a stimulus for inﬂammation as well as for beta amyloid
production and deposition. Precedence for infection in exacer-
bating AD-like pathology has been reported for other types of
infections in different animalmodels (McManus et al., 2014;Wang
et al., 2014). Once the infection has been controlled or resolved
completely, levels of soluble amyloid apparently decrease presum-
ably following internalization by glial cells (Hawkes et al., 2012)
and/or washout into the blood, thereby resulting in fewer deposits
documented at the 3 and 4 month timepoints. These ﬁndings
support our contention that laboratory strains of Cpn from res-
piratory infections as compared to Cpn brain isolates are less
capable of creating long-standing damage in the CNS. In this
regard, at the present time, we do not know what inoculum
of Cpn is sufﬁcient to not only initiate but to promote chronic
human disease, nor do we understand potentially different viru-
lence factors of Cpn isolated fromdifferent tissue sites. Our animal
studies do support our contention that infection (even in modest
titers – 105 organisms), speciﬁcally through an intranasal route,
can initiate changes in the brain consistent with early AD-like
pathology.
FIGURE 4 | Beta amyloid Aβ 1–42 deposits in the CNS at 2 months pi
following intranasal infection with Chlamydia pneumoniae AR-39.
Brains were examined by light microscopy for the presence of Aβ 1–42
using a speciﬁc anti-Aβ 1–42 antibody. (A–E) Representative images of Aβ
1–42-speciﬁc labeling (arrowheads) are shown within different regions of
this brain section. Ect (entorhinal cortex), L Ent (lateral entorhinal cortex), Th
(thalamus), Prh (perirhinal cortex), Cp (cerebral peduncle). Mag bars
(A) = 100μm; (B–E) = 20 μm.
In mice infected with the 96-41 Cpn brain isolate, deposits of
Aβ-amyloid could be identiﬁed as early as 2 months pi, with the
greatest numbers at 3months pi. Furthermore, the increase in both
number and size of amyloid deposits suggested the development
of progressive AD-like pathology. This is an important issue as
early initiating events resulting in sporadic late-onset AD have not
been addressed using genetically modiﬁed transgenic models that
principally emulate familial AD, not the more common late-onset
form of disease. Further, experimental animal systems intended
to model sporadic late-onset AD have been limited by the absence
in understanding speciﬁc factors that initiate or promote the early
deposition of Aβ-amyloid prior to the onset of symptomatic ill-
ness; however, numerous experimentally induced animal models
utilizing direct injection of microbial products have been shown
to induce transient amyloid production and deposition (Erickson
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et al., 2012; Krstic et al., 2012). Our current study with a respira-
tory isolate of Cpn supports the induction of transient amyloid
deposition and contrasts with our previous work suggesting that a
brain isolate of Cpn results in progressive amyloid accumulation.
Interestingly, a previous study did not identify substantial AD-
like pathology in the brain using the respiratory isolate TWAR
2043, a commonly studied laboratory strain of Cpn (Boelen et al.,
2007). Boelen et al. (2007) infected BALB/c mice intranasally, and
at one and 3 months pi examined brain tissue on the assumption
that, both, TWAR 2043 and the AD brain isolate 96-41 reported
by Little et al. (2004) would induce similar patterns of pathology
following infection. Amyloid beta deposits were reported as 1 or
2 aggregates per section without a preference for a certain brain
region in the Boelen et al. (2007) study, and the researchers indi-
cated that Cpn was undetectable in the CNS at 1 or 3 months
pi. Both mock-infected and Cpn-infected mice exhibited no dif-
ference in the number of amyloid deposits. The clear difference
noted from the Little et al. (2004) study of total number and size of
deposits was notably different from the Boelen et al. (2007) report.
It was proposed by Boelen et al. (2007) that discrepancies between
reports could have arisen because the TWAR 2043 Cpn strain may
have different virulence properties than the 96-41 AD-brain iso-
late (Balin et al., 2011). It has been observed and we concur that
isolates of Cpn propagated long-term in culture may differ sub-
stantially from primary respiratory specimens.With respect to the
ability to establish a persistent infection and subsequent induction
of pathology, TWAR 2043 and 96-41 appear to display different
phenotypes in the brains of BALB/c mice.
Our current ﬁndings support the contention that isolates of
Cpn may differ in their ability to establish chronic or persistent
infection and promote progressive pathology. Numerous ques-
tions remain as to the nature of the organisms that typically
infect the human population. Pertinent issues, just to name a
few, include: risk factors promoting infection at speciﬁc sites
in the body, spread into different tissues and organs follow-
ing initial infection, virulence factors expressed by the organism
and/or host response, and age at which infection occurs. With
regards to age, a prior study of Cpn infection in older ani-
mals suggests that older age at time of infection promotes the
establishment of a brain infection (Little et al., 2005). Further,
to address our current study that a modest inoculum of a res-
piratory isolate of Cpn initiated speciﬁc but non-sustainable
change in the brain following intranasal inoculation, we prelim-
inarily inoculated a small group of animals with Cpn AR-39,
either twice (days 0 and 30), or three times (days 0, 30, and
60) and sacriﬁced at day 90, and found that individual BALB/c
mice inoculated twice displayed 68 amyloid deposits per mouse
and those inoculated three times had 177 amyloid deposits per
mouse (unpublished observations). In comparison,mice receiving
only a single intranasal inoculation as observed in the cur-
rent study at 3 months pi had an average of 17–18 deposits
per mouse (53 deposits/3 mice; see Table 1A). These prelimi-
nary observations would suggest that multiple inocula of Cpn
may exacerbate pathology in the brain, but further experiments
are required to clarify this. Furthermore, respiratory or blood-
borne organisms may become altered after invading different
tissue sites including the brain and this may reﬂect biovar and
serovar differences with Cpn, although this remains to be deter-
mined. Future sequencing analyses and speciﬁc characterization
of different tissue and organ isolates may help to resolve these
issues.
In summary, Cpn appears to be a primary trigger for the
generation and extracellular deposition of Aβ-amyloid in our
mouse model. The differences in progressive as compared to non-
progressive pathologymay be due to strain variations. This implies
that virulence factors and tissue tropism of the organism as well
as numerous host factors all contribute to determine the overall
pathogenicity of different isolates of Cpn in particular tissues fol-
lowing intranasal infection and subsequent dissemination (Balin
et al., 2011). Thus, in concert, host and pathogen interactions ini-
tiate detrimental processes that, if left unchecked, may progress to
the disease state.
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